Alpine Immune Sciences presented new data on povetacicept (ALPN-303) at the 14th European Lupus Meeting, demonstrating improved distribution and significant reduction in disease parameters in a mouse model.
Alpine Immune Sciences showcased new translational data on povetacicept (ALPN-303) at the 14th European Lupus Meeting, demonstrating greater distribution to disease-related end organs than WT TACI-Ig. A phase 2 study (DENALI) for systemic lupus erythematosus (SLE) is planned for initiation in H2 2024. Povetacicept significantly reduced disease parameters in NZB/W mouse lupus model, outperforming WT TACI-Ig or B cell depletion.
March 21, 2024
3 Articles